Note 9 – Subsequent Events

On July 20, 2026, the Company entered into a definitive license agreement with PharmAla Biotech Holdings Inc. (“PharmAla”) for perpetual exclusive U.S. rights to ALA-002. In connection with the agreement, the Company made an additional $900,000 cash payment, for a total upfront cash consideration of $1.5 million and is to issue PharmAla $1.83 million in equity securities for a total upfront consideration of $3.33 million. See further details in Note 1 – Organization and Description of Business.

Subsequent to June 30, 2026 and through the date of this filing, the Company sold 105,413 shares of common stock under the SEPA at an average price of $13.55 per share, resulting in gross proceeds of $1,428,864.

At the July 22, 2026 Annual Meeting, the Company’s stockholders also approved an amendment to the 2025 Equity Incentive Plan to increase the number of shares available for issuance by 5,250,000 pre-split shares, equivalent to 70,000 post-split shares after giving effect to the Reverse Stock Split.